Doi, H., Matsuo, Y., Kishi, N., Ogura, M., Mitsuyoshi, T., Ueki, N., . . . Mizowaki, T. (2025). Optimal Duration of Consolidation Durvalumab Following Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer: A Multi-institutional Retrospective Study: Duration of Durvalumab Following CCRT in Stage III NSCLC: H. Doi et al. Targeted Oncology, 20(1), 161-170.
Copiado correctamente al portapapeles
Error al copiar al portapapeles
Cita Chicago Style (17a ed.)
Doi, Hiroshi, et al. "Optimal Duration of Consolidation Durvalumab Following Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer: A Multi-institutional Retrospective Study: Duration of Durvalumab Following CCRT in Stage III NSCLC: H. Doi Et Al."
Targeted Oncology 20, no. 1 (2025): 161-170.
Copiado correctamente al portapapeles
Error al copiar al portapapeles
Cita MLA (9a ed.)
Doi, Hiroshi, et al. "Optimal Duration of Consolidation Durvalumab Following Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer: A Multi-institutional Retrospective Study: Duration of Durvalumab Following CCRT in Stage III NSCLC: H. Doi Et Al."
Targeted Oncology, vol. 20, no. 1, 2025, pp. 161-170.
Copiado correctamente al portapapeles
Error al copiar al portapapeles
Precaución: Estas citas no son 100% exactas.